Hepatocellular carcinoma (HCC) is a leading cause of cancer-related mortality with a rapidly changing landscape of treatments. In the past 20 years, numerous randomized controlled trials (RCT) have aimed at improving outcomes across disease stages. We aimed at analyzing the current evidence and identifying potential factors influencing response to therapies.